Diamond Biofund: Pioneering Success in Biotechnology Venture Capital

Diamond Biofund, a venture capital firm based in Taipei, has achieved impressive success in the biotechnology sector, delivering a significant return to its founding partners. Founded in 2013, the fund has achieved an impressive 17 times return on investment in just ten years. These partners include Daniel and Richard Tsai, well-known figures in Fubon Financial Holding, and Thomas Wu, the Chairman of Taishin Holdings. Samuel Yin, who oversees Ruentex Group, also profited from the fund's success, as each company initially contributed $31 million to the venture.

With its relatively short tenure, Diamond Biofund has made remarkable contributions to the biotech and healthcare industries by incubating and investing in more than 20 companies. One of the noteworthy investments is Oneness Biotech, a Taiwanese pharmaceutical company that focuses on dermatology and immunology disorders. It went public in 2011 and currently has a market capitalization of over $2 billion. In 2013, Yin had a forward-thinking perspective for the industry, and now, in September 2023, Diamond Biofund has achieved a remarkable feat by being listed on the Taiwanese stock exchange, a major accomplishment for the region’s biotechnology.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Read more